Evidence map›Paper›PMID 33604784›Full record

ArticlePharmaceutical research2021

Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.

Sara Rhaissa Rezende do Reis, Edward Helal-Neto, Aline Oliveira da Silva de Barros, Suyene Rocha Pinto, Filipe Leal Portilho, Luciana Betzler de Oliveira Siqueira, Luciana Magalhães Rebelo Alencar, Si Amar Dahoumane, Frank Alexis, Eduardo Ricci-Junior and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Sara Rhaissa Rezende do ReisBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, Brazil.
Edward Helal-NetoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, Brazil.
Aline Oliveira da Silva de BarrosBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, Brazil.
Suyene Rocha PintoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, Brazil.
Filipe Leal PortilhoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, Brazil.
Luciana Betzler de Oliveira SiqueiraFaculty of Pharmacy, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.
Luciana Magalhães Rebelo AlencarPhysics Department, Federal University of Maranhão, São Luís, Maranhão, Brazil.
Si Amar DahoumaneSchool of Biological Sciences and Engineering, Yachay Tech, 100650, San Miguel de Urcuquí, Imbabura, Ecuador.
Frank AlexisSchool of Biological Sciences and Engineering, Yachay Tech, 100650, San Miguel de Urcuquí, Imbabura, Ecuador.
Eduardo Ricci-JuniorFaculty of Pharmacy, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.
Ralph Santos-OliveiraBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, Brazil. roliveira@ien.gov.br.ORCID http://orcid.org/0000-0002-0905-481X
Nuclear Engineering Institute · BRUniversidade Federal do Rio de Janeiro · BRUniversidad Yachay Tech · ECUniversidade Estadual da Zona Oeste · BRUniversidade Federal do Maranhão · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMelanoma is an invasive and very aggressive skin cancer due to its multi-drug resistance that results in poor patient survival. There is a need to test new treatment approaches to improve therapeutic efficacy and reduce side effects of conventional treatments.

methodsPLA/PVA nanoparticles carrying both Dacarbazine and zinc phthalocyanine was produced by double emulsion technique. The characterization was performed by dynamic light scattering and atomic force microscopy. In vitro photodynamic therapy test assay using MV3 melanoma cells as a model has been performed. In vitro cell viability (MTT) was performed to measure cell toxicity of of nanoparticles with and without drugs using human endothelial cells as a model. The in vivo assay (biodistribution/tissue deposition) has been performed using radiolabeled PLA/PVA NPs.

resultsThe nanoparticles produced showed a mean diameter of about 259 nm with a spherical shape. The in-vitro photodynamic therapy tests demonstrated that the combination is critical to enhance the therapeutic efficacy and it is dose dependent. The in vitro cell toxicity assay using endothelial cells demonstrated that the drug encapsulated into nanoparticles had no significant toxicity compared to control samples. In-vivo results demonstrated that the drug loading affects the biodistribution of the nanoparticle formulations (NPs). Low accumulation of the NPs into the stomach, heart, brain, and kidneys suggested that common side effects of Dacarbazine could be reduced.

conclusionThis work reports a robust nanoparticle formulation with the objective to leveraging the synergistic effects of chemo and photodynamic therapies to potentially suppressing the drug resistance and reducing side effects associated with Dacarbazine. The data corroborates that the dual encapsulated NPs showed better in-vitro efficacy when compared with the both compounds alone. The results support the need to have a dual modality NP formulation for melanoma therapy by combining chemotherapy and photodynamic therapy.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingCell Line, TumorCell SurvivalDacarbazineDrug CarriersDrug CompoundingEndothelial CellsHumansIsoindolesMaleMelanomaMiceNanoparticlesOrganometallic CompoundsPhotochemotherapyAntineoplastic Agents, AlkylatingDacarbazineDrug CarriersIsoindolesOrganometallic CompoundsPhotosensitizing AgentsPolyesterspoly(lactide)Polyvinyl AlcoholZinc CompoundsZn(II)-phthalocyaninedacarbazinedrug resistancemelanomananoparticlephotodynamic therapy

Identifiers

PMID33604784
OpenAlexW3131892011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.